The HIP1 Knockout HT29 Polyclonal Cells are a genetically modified cell population in which the HIP1 gene has been disrupted via CRISPR/Cas9-mediated editing. Derived from the HT29 colorectal adenocarcinoma cell line, this product is provided as a polyclonal knockout pool, offering a heterogeneous loss-of-function model that minimizes clonal selection artifacts. This format is ideal for population-level studies of endocytosis, receptor trafficking, and signaling pathways where broad genetic perturbation is required.
The HT29 parental line originates from a colorectal adenocarcinoma of a 44-year-old female and is a well-established model for intestinal epithelial cell differentiation and colorectal cancer. HT29 cells exhibit heterogeneous differentiation capacity under appropriate culture conditions, reflecting tumor cell plasticity and enabling investigations into differentiation-dependent signaling. This background is particularly relevant for examining the interplay between endocytic machinery and oncogenic processes in colorectal adenocarcinoma.
HIP1 encodes a conserved adaptor protein that bridges clathrin-coated vesicle formation and the actin cytoskeleton during endocytosis. It directly interacts with clathrin, the AP-2 adaptor complex, actin filaments, and huntingtin to facilitate internalization of cargo such as the epidermal growth factor receptor (EGFR). Upstream, HIP1 is regulated by EGF and receptor tyrosine kinases, and downstream, it promotes EGFR degradation and receptor downregulation, thereby attenuating signaling. Additionally, HIP1 exhibits pro-apoptotic functions and is linked to the Huntington’s disease pathway through its interaction with huntingtin.
In the context of HT29 colorectal adenocarcinoma cells, knockout of HIP1 disrupts clathrin-mediated endocytosis, resulting in impaired EGFR internalization and trafficking. This leads to sustained surface EGFR levels and altered downstream phosphorylation cascades, potentially affecting cell proliferation, survival, and migration. The model is particularly valuable for studying how endocytic dysfunction contributes to colorectal cancer progression and drug sensitivity, given the critical role of EGFR signaling in this tumor type. Moreover, the huntingtin interaction provides a unique opportunity to explore Huntington’s disease-related mechanisms in an epithelial cancer cell background.
These polyclonal knockout cells support a wide range of experimental applications, including mechanistic dissection of endocytosis, quantitative analysis of receptor trafficking and recycling, and functional assays of cancer cell signaling. Researchers can employ western blotting to assess HIP1 and EGFR expression, immunofluorescence to visualize clathrin localization and EGFR internalization, flow cytometry to measure surface EGFR, co-immunoprecipitation to detect HIP1-clathrin interactions, and migration or invasion assays to evaluate phenotypic changes. The model is also applicable for studying drug delivery via endocytic pathways and for Huntington’s disease research. For additional technical details, please contact Ascent Research.
